CoreWeave Raises FY2026 Revenue Outlook to $13B, Cites 10x AI Demand Through 2027

What happened

CoreWeave revised its full-year 2026 revenue guidance upward to $13.0–13.3 billion, up from prior expectations, while management stated that AI demand through 2027 is roughly 10 times its currently contracted capacity. This demand signal aligns with the company's existing backlog of approximately $104 billion as of June 30, 2026, but does not address the core challenge of converting financed capacity into billable utilization quickly enough to outrun mounting interest and depreciation costs. The raised outlook implies a significant acceleration in second-half revenue recognition, requiring flawless execution on power activation and GPU commissioning that has historically been a source of slippage. Despite the positive demand commentary, the company's balance sheet remains strained with $35.6 billion of debt and $16.3 billion of lease liabilities, and GAAP operating losses persist. Investors should view this update as confirmation of demand strength but not yet as proof that CoreWeave can generate positive owner earnings without additional dilution or higher-cost financing.

Implication

The raised revenue guidance and 10x demand claim reinforce that customers are willing to pay for GPU capacity, but CoreWeave's ability to deliver that capacity on time remains the key swing factor. Investors should focus on Q3 2026 actuals, which need to land within $3.45–3.60 billion to validate the June power ramp and support the full-year outlook. If Q3 revenue meets guidance and commenced-delivery backlog exceeds two-thirds by year-end, the stock could re-rate higher as the market shifts focus from financing fears to installed earning power. Conversely, any shortfall in Q3 revenue or a further increase in debt and interest expense would intensify concerns about the company's leverage and execution. We would consider adding only on a pullback to the $90 attractive entry level or on clear evidence that commissioning delays are resolved; trimming above $130 remains appropriate given the asymmetric risk.

Thesis delta

The thesis remains unchanged: CoreWeave's demand is not the issue, but execution and financing are. The raised outlook and 10x demand statement provide incremental confidence in backlog quality, but they do not mitigate the risk that capacity additions will be delayed or that financing costs will erode profitability. Therefore, we maintain the WAIT rating and $112 base-case implied value.